Chicago Capital LLC Takes Position in Exact Sciences Co. (NASDAQ:EXAS)

Chicago Capital LLC acquired a new stake in shares of Exact Sciences Co. (NASDAQ:EXAS) during the 3rd quarter, Holdings Channel.com reports. The institutional investor acquired 4,451 shares of the medical research company’s stock, valued at approximately $303,000.

Several other institutional investors have also recently modified their holdings of EXAS. PNC Financial Services Group Inc. grew its position in Exact Sciences by 30.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 18,191 shares of the medical research company’s stock worth $1,346,000 after acquiring an additional 4,258 shares during the last quarter. Mather Group LLC. bought a new position in Exact Sciences during the 1st quarter worth approximately $79,000. Banque Cantonale Vaudoise grew its position in Exact Sciences by 35.6% during the 1st quarter. Banque Cantonale Vaudoise now owns 6,841 shares of the medical research company’s stock worth $472,000 after acquiring an additional 1,795 shares during the last quarter. Park Avenue Securities LLC grew its position in Exact Sciences by 33.7% during the 1st quarter. Park Avenue Securities LLC now owns 28,400 shares of the medical research company’s stock worth $1,961,000 after acquiring an additional 7,151 shares during the last quarter. Finally, AdvisorNet Financial Inc grew its position in Exact Sciences by 16.5% during the 1st quarter. AdvisorNet Financial Inc now owns 10,302 shares of the medical research company’s stock worth $711,000 after acquiring an additional 1,461 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on EXAS. Wells Fargo & Company began coverage on Exact Sciences in a research report on Tuesday, August 27th. They set an “overweight” rating and a $75.00 price target on the stock. Benchmark dropped their price objective on Exact Sciences from $91.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Evercore ISI increased their price objective on Exact Sciences from $72.00 to $80.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Canaccord Genuity Group reiterated a “buy” rating and issued a $75.00 price objective on shares of Exact Sciences in a report on Friday, September 13th. Finally, Scotiabank began coverage on Exact Sciences in a report on Thursday, June 27th. They issued a “sector outperform” rating and a $70.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $78.38.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, EVP Brian Baranick sold 929 shares of Exact Sciences stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the completion of the transaction, the executive vice president now owns 12,758 shares in the company, valued at approximately $893,060. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.36% of the stock is owned by company insiders.

Exact Sciences Trading Up 3.9 %

EXAS opened at $71.93 on Monday. The stock has a market cap of $13.27 billion, a PE ratio of -54.49 and a beta of 1.27. The company has a quick ratio of 1.98, a current ratio of 2.17 and a debt-to-equity ratio of 0.73. The business has a 50 day moving average of $64.58 and a 200-day moving average of $56.64. Exact Sciences Co. has a 52 week low of $40.62 and a 52 week high of $79.62.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.28. The business had revenue of $699.26 million during the quarter, compared to analysts’ expectations of $690.02 million. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.45) earnings per share. Equities research analysts predict that Exact Sciences Co. will post -0.87 earnings per share for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.